Cholesterol Biosynthesis and the Mevalonate Pathway - Biochemistry

SECTION 1

Historical Context & Motivation

Cholesterol has occupied a central position in biochemistry since the early nineteenth century, when the French chemist Michel Eugène Chevreul first isolated a waxy substance from gallstones and named it cholestérine (from the Greek chole, bile, and stereos, solid). For more than a century after that discovery, the question of how animal cells manufacture this complex 27-carbon molecule from simple two-carbon precursors remained one of the most challenging puzzles in metabolism. Solving that puzzle required isotopic tracer experiments, the identification of dozens of enzymatic intermediates, and the elucidation of an elaborate regulatory network—a story that earned multiple Nobel Prizes and ultimately gave rise to the statin drug class, one of the most widely prescribed medications in the world.

1816 • Isolation of Cholesterol

Chevreul isolates cholesterol from gallstones, establishing it as a distinct lipid species.

1926–1942 • Isotopic Tracer Experiments

Konrad Bloch and David Rittenberg use deuterium-labeled acetate to show that all 27 carbons of cholesterol derive from acetate (acetyl-CoA), a landmark finding.

1956 • Mevalonate Identified

Karl Folkers and colleagues at Merck discover mevalonic acid, the six-carbon branching-point intermediate, closing a critical gap between acetyl-CoA and squalene.

1964 • Nobel Prize to Bloch & Lynen

Konrad Bloch and Feodor Lynen share the Nobel Prize in Physiology or Medicine for elucidating the biosynthetic pathway from acetyl-CoA to cholesterol.

1985 • Brown & Goldstein — HMG-CoA Reductase Regulation

Michael Brown and Joseph Goldstein receive the Nobel Prize for discovering the SREBP-mediated regulation of HMG-CoA reductase and LDL receptor expression, providing the biochemical rationale for statin therapy.

Against this backdrop, the central question driving this lesson emerges: how does a cell convert a simple two-carbon acetyl group into a complex polycyclic sterol through a pathway involving more than 30 enzymatic steps, and how is that pathway regulated so precisely that cellular cholesterol levels remain within a narrow homeostatic range?

SECTION 2

Core Principles of Cholesterol Biosynthesis

Before diving into the individual reactions, it is important to appreciate the overarching logic of cholesterol biosynthesis. The pathway can be conceptualized as a four-stage construction project: first, small building blocks are assembled; second, those blocks are activated and polymerized into a long hydrocarbon chain; third, that chain undergoes cyclization into a steroid nucleus; and fourth, the initial product is modified to yield cholesterol. Several unifying principles govern every stage.

Acetyl-CoA Is the Universal Carbon Donor

All 27 carbons of cholesterol originate from acetyl-CoA. The pathway begins in the cytosol with the condensation of acetyl-CoA units into the six-carbon compound mevalonate.

Isoprene Units as Modular Building Blocks

Mevalonate is decarboxylated to yield five-carbon isopentenyl pyrophosphate (IPP), the 'activated isoprene' unit. Cholesterol is thus an isoprenoid constructed from six isoprene modules.

HMG-CoA Reductase — The Committed Step

The reduction of HMG-CoA to mevalonate by HMG-CoA reductase is the rate-limiting, committed step. This enzyme is the target of statin drugs and is tightly regulated at transcriptional, translational, and post-translational levels.

Reductive Biosynthesis Requires NADPH

Cholesterol is far more reduced than its acetyl-CoA precursors. The pathway consumes large quantities of NADPH (primarily from the pentose phosphate pathway) to supply the necessary reducing equivalents—approximately 16 NADPH per cholesterol molecule.

Oxygen-Dependent Modifications

The later stages of the pathway, including squalene epoxidation and lanosterol demethylation, require molecular oxygen (O₂). This makes de novo cholesterol synthesis an exclusively aerobic process.

✦

KEY TAKEAWAY

Think of cholesterol biosynthesis as building a house from lumber. Acetyl-CoA molecules are the raw timber; they are first cut into standard-length boards (isoprene units), then nailed together into walls (squalene), and finally framed into the finished structure (the steroid ring system). The foreman on the job site—HMG-CoA reductase—decides how fast construction proceeds, and is the key point at which the entire project can be sped up or shut down.

SECTION 3

The Mevalonate Pathway — Visual Overview

The following diagram traces the major intermediates of cholesterol biosynthesis from cytosolic acetyl-CoA through to lanosterol, the first sterol intermediate. The pathway is divided into four stages represented by distinct color zones: Stage 1 (synthesis of mevalonate), Stage 2 (formation of activated isoprene units), Stage 3 (assembly of squalene), and Stage 4 (cyclization to lanosterol and conversion to cholesterol).

Figure 1. The mevalonate pathway from acetyl-CoA to cholesterol divided into four stages. The red box marks statin inhibition at HMG-CoA reductase. IPP = isopentenyl pyrophosphate; GPP = geranyl pyrophosphate; FPP = farnesyl pyrophosphate. Note the overall stoichiometry at bottom.

As the diagram illustrates, the early stages of the pathway (Stages 1 and 2) occur in the cytosol, whereas the later stages (Stages 3 and 4) take place on the endoplasmic reticulum membrane. Squalene synthase, the enzyme that dimerizes two farnesyl pyrophosphate molecules, is the first membrane-bound enzyme in the pathway and therefore represents a critical branch point: intermediates upstream of squalene synthase are also precursors of non-sterol isoprenoids such as ubiquinone, dolichol, and prenylated proteins.

SECTION 4

Enzymatic Mechanisms — Stage by Stage

Stage 1 — Formation of Mevalonate

The first stage comprises three enzymatic steps. Thiolase (acetoacetyl-CoA thiolase) catalyzes a Claisen condensation of two acetyl-CoA molecules to form acetoacetyl-CoA (C₄), releasing one CoA. Next, HMG-CoA synthase condenses a third acetyl-CoA with acetoacetyl-CoA via an aldol-like mechanism to yield 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), a branched-chain C₆ thioester. The rate-limiting step follows: HMG-CoA reductase catalyzes a four-electron reduction of HMG-CoA to mevalonate, consuming two molecules of NADPH. This is the committed step of the pathway, meaning that once mevalonate is formed, the carbon is irrevocably destined for isoprenoid biosynthesis.

HMG-CoA REDUCTASE REACTION

HMG-CoA + 2 NADPH + 2 H⁺ → Mevalonate + 2 NADP⁺ + CoA-SH

This four-electron reduction converts the thioester to a primary alcohol. The reaction is essentially irreversible under physiological conditions (ΔG°' ≈ −33 kJ/mol), providing the thermodynamic drive for commitment to the pathway.

Stage 2 — Activation to Isoprene Units

Mevalonate undergoes three sequential ATP-dependent phosphorylations and a decarboxylation. Mevalonate kinase and phosphomevalonate kinase produce mevalonate-5-pyrophosphate, which is then decarboxylated by mevalonate-5-pyrophosphate decarboxylase to yield the five-carbon isopentenyl pyrophosphate (IPP). IPP is in equilibrium with its isomer dimethylallyl pyrophosphate (DMAPP) through the action of isopentenyl pyrophosphate isomerase. DMAPP is the electrophilic primer onto which IPP molecules are added head-to-tail.

MEVALONATE TO IPP

Mevalonate + 3 ATP → IPP (C₅) + 3 ADP + Pᵢ + CO₂

The loss of one carbon as CO₂ explains why cholesterol (C₂₇) is built from 18 acetyl-CoA molecules (36 carbons − 9 CO₂ = 27 carbons in the final product, after accounting for squalene's C₃₀ intermediate).

Stage 3 — Polymerization to Squalene

Sequential head-to-tail condensations, catalyzed by prenyl transferases, elongate the isoprenoid chain. DMAPP (C₅) + IPP (C₅) → geranyl pyrophosphate (GPP, C₁₀); GPP + IPP → farnesyl pyrophosphate (FPP, C₁₅). Squalene synthase then joins two FPP molecules in a head-to-head condensation with concomitant loss of both pyrophosphate groups and a reductive rearrangement (consuming one NADPH) to produce the linear C₃₀ hydrocarbon squalene.

Stage 4 — Cyclization and Modification to Cholesterol

Squalene is epoxidized by squalene monooxygenase (a mixed-function oxidase requiring O₂ and NADPH) to form squalene-2,3-epoxide. Oxidosqualene cyclase (lanosterol synthase) then catalyzes one of the most remarkable reactions in biochemistry: a concerted cyclization of the linear squalene epoxide into the tetracyclic sterol lanosterol. This single enzyme forms four rings, six carbon–carbon bonds, and seven stereocenters in one catalytic cycle. Lanosterol is subsequently converted to cholesterol through approximately 19 additional steps that involve the removal of three methyl groups, reduction of a double bond in the side chain, and migration of the Δ⁸ double bond to the Δ⁵ position.

SECTION 5

Regulation of Cholesterol Biosynthesis

Because cholesterol excess is cytotoxic and its deficiency impairs membrane function, cells deploy an extraordinarily multilayered regulatory system centered on HMG-CoA reductase. The enzyme is regulated at no fewer than four levels: transcriptional control via SREBPs, translational regulation, accelerated proteolytic degradation, and covalent modification by phosphorylation. These mechanisms ensure that cellular cholesterol levels are maintained within a tightly controlled homeostatic range.

Figure 2. Four levels of HMG-CoA reductase regulation. Green arrows indicate activation (low-cholesterol conditions); red arrows indicate inhibition (high-cholesterol conditions). SREBP = sterol regulatory element–binding protein; SCAP = SREBP-cleavage-activating protein; Insig = insulin-induced gene protein; AMPK = AMP-activated protein kinase.

The SREBP (sterol regulatory element–binding protein) pathway deserves particular emphasis because it provides transcriptional feedback. When ER membrane cholesterol falls below approximately 5 mol%, the cholesterol-sensing protein SCAP undergoes a conformational change that releases it from Insig (an ER-retention anchor). SCAP then escorts SREBP-2 in COPII-coated vesicles to the Golgi, where two sequential proteases (S1P and S2P) release the N-terminal basic helix-loop-helix (bHLH) transcription factor domain. This fragment translocates to the nucleus and binds sterol regulatory elements (SREs) in the promoters of more than 30 genes involved in cholesterol and fatty acid synthesis, including HMG-CoA reductase, HMG-CoA synthase, and the LDL receptor.

ℹ

Clinical Connection — Statins

Statins (e.g., atorvastatin, rosuvastatin) are structural analogs of HMG-CoA and act as competitive inhibitors of HMG-CoA reductase with K_i values in the low nanomolar range. By reducing hepatic cholesterol synthesis, statins trigger an increase in SREBP-mediated transcription of the LDL receptor gene, which in turn lowers plasma LDL-cholesterol by 25–55%. This mechanism was predicted from the Brown and Goldstein model of SREBP regulation.

SECTION 6

Worked Example — Carbon and Cofactor Accounting

A classic exam question asks students to trace the carbon atoms and calculate the stoichiometric requirements for cholesterol biosynthesis from acetyl-CoA. The following worked example walks through this calculation step by step.

How many acetyl-CoA, ATP, and NADPH are consumed to synthesize one molecule of cholesterol?

1
Step 1 — Count carbons in cholesterol

Cholesterol has the molecular formula C₂₇H₄₆O. It contains 27 carbon atoms. Each acetyl-CoA supplies 2 carbons. However, carbons are lost as CO₂ during the decarboxylation of mevalonate to IPP. We must account for these losses.
2
Step 2 — Trace carbons through mevalonate and IPP

Three acetyl-CoA molecules (6 carbons) form one mevalonate (C₆). Mevalonate is then decarboxylated to IPP (C₅), losing one CO₂. Thus, every 3 acetyl-CoA → 1 IPP (5 carbons utilized, 1 carbon lost as CO₂).
3
Step 3 — Determine the number of isoprene units in cholesterol

Squalene (C₃₀) is assembled from 6 IPP/DMAPP units (6 × 5 = 30 carbons). After cyclization, three methyl groups are removed (as CO₂ or formate) in converting lanosterol (C₃₀) to cholesterol (C₂₇). So in total: 6 IPP units require 6 × 3 = 18 acetyl-CoA. The 18 acetyl-CoA supply 36 carbons; 6 are lost as CO₂ during IPP formation and 3 more during demethylation (total 9 CO₂ lost), leaving 27 carbons.

18 acetyl-CoA required
4
Step 4 — Count ATP molecules

Each mevalonate → IPP conversion requires 3 ATP (mevalonate kinase, phosphomevalonate kinase, and decarboxylase each consume 1 ATP). Six IPP units × 3 ATP per IPP = 18 ATP. However, condensation reactions forming squalene consume pyrophosphate (PPᵢ), and the overall bookkeeping (accounting for pyrophosphate hydrolysis as equivalent to an additional ATP) brings the total to approximately 36 ATP when all activating steps and pyrophosphate-driven reactions are considered.

36 ATP consumed
5
Step 5 — Count NADPH molecules

HMG-CoA reductase uses 2 NADPH per mevalonate. With 6 mevalonate molecules, that accounts for 12 NADPH. Squalene synthase requires 1 NADPH. Squalene monooxygenase requires 1 NADPH. The remaining ~2 NADPH are consumed in the lanosterol-to-cholesterol conversions (reductions and oxidative demethylations). The widely cited total is 16 NADPH.

16 NADPH consumed
6
Step 6 — Write the overall stoichiometry

Combining all inputs and outputs:

18 Acetyl-CoA + 36 ATP + 16 NADPH + 16 H⁺ + O₂ → Cholesterol + 9 CO₂ + 18 CoA-SH + 36 ADP + 36 Pᵢ + 16 NADP⁺

SECTION 7

Functions of Cholesterol and Pathway Branches

Cholesterol is not merely a structural lipid; it serves as the precursor for a variety of essential biomolecules. The mevalonate pathway also branches to produce several non-sterol isoprenoids that are critical for cellular function. Understanding these downstream fates is important both for biochemistry courses and for appreciating why over-inhibition of the pathway can have unintended side effects.

Product	Pathway Branch Point	Biological Function
Cholesterol	Squalene → lanosterol → cholesterol	Membrane fluidity modulator, lipid raft component, precursor for bile acids, steroid hormones, and vitamin D
Ubiquinone (CoQ₁₀)	FPP → polyprenyltransferase	Mobile electron carrier in mitochondrial electron transport chain (Complex I → III)
Dolichol	FPP → cis-prenyltransferase	Lipid carrier for N-linked glycosylation in the ER lumen
Prenylated proteins (Ras, Rho)	FPP or GGPP → farnesyltransferase / geranylgeranyltransferase	Membrane anchoring and activation of small GTPases essential for cell signaling and proliferation
Heme A	FPP → farnesylation of heme	Prosthetic group of cytochrome c oxidase (Complex IV)

Table 1. Products of the mevalonate/isoprenoid pathway and their biological roles.

✦

KEY TAKEAWAY

The mevalonate pathway is not a one-product assembly line—it is more like a chemical supply chain with multiple distribution centers. FPP sits at the central hub: some FPP is routed toward cholesterol, some toward ubiquinone, some toward dolichol, and some toward protein prenylation. This branching architecture explains why statin therapy, while beneficial for lowering cholesterol, can occasionally deplete CoQ₁₀ and may contribute to the myopathy observed in a subset of patients.

SECTION 8

Connections to Advanced Topics

Cholesterol biosynthesis intersects with numerous advanced topics in metabolism, pharmacology, and disease. The table below contrasts the foundational pathway concepts covered in this lesson with more advanced considerations that students may encounter in graduate-level biochemistry, pharmacology, or medical biochemistry courses.

Foundational Concept	Advanced Extension
HMG-CoA reductase is the rate-limiting step	Squalene synthase and ACAT (acyl-CoA:cholesterol acyltransferase) represent additional flux-control points studied in metabolic control analysis
SREBP transcriptional regulation	LXR (liver X receptor) and FXR (farnesoid X receptor) nuclear receptor cross-talk; oxysterol sensing and feedback beyond the ER
Statins as competitive inhibitors	PCSK9 inhibitors (monoclonal antibodies and siRNA), bempedoic acid (ATP-citrate lyase inhibitor), and ezetimibe (NPC1L1 cholesterol absorption blocker) as complementary therapeutic strategies
Lanosterol → cholesterol (~19 steps)	Bloch vs. Kandutsch-Russell pathway divergence at the level of C₂₄ reduction; tissue-specific pathway preference (brain vs. liver)
Cholesterol as membrane component	Hedgehog signaling requires covalent cholesterol modification of Hh proteins; Smith-Lemli-Opitz syndrome (DHCR7 deficiency) as an inborn error of cholesterol biosynthesis

Table 2. Foundational vs. advanced topics in cholesterol metabolism.

As these connections illustrate, the mevalonate pathway provides a framework for understanding not only lipid metabolism but also signaling biology, drug design, and genetic disease. Students planning careers in pharmacology or medicine will revisit these concepts repeatedly when studying dyslipidemia, atherosclerosis, and prenylation-dependent oncogenesis.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Why is the HMG-CoA reductase reaction, rather than the thiolase or HMG-CoA synthase reaction, considered the committed step of cholesterol biosynthesis? What distinguishes a committed step from a rate-limiting step, and are both terms applicable here?

Show answer

The committed step is the first irreversible reaction unique to a pathway that diverts metabolites from alternative fates. Thiolase and HMG-CoA synthase produce intermediates (acetoacetyl-CoA, HMG-CoA) that also participate in ketogenesis. Only after HMG-CoA is reduced to mevalonate—a thermodynamically irreversible reaction (ΔG°' ≈ −33 kJ/mol)—is the carbon committed to isoprenoid synthesis. In this pathway, the committed step and the rate-limiting step coincide at HMG-CoA reductase, but this is not always the case in every metabolic pathway; sometimes the slowest step differs from the first irreversible unique step.

Question 2: BASIC CALCULATION

If a hepatocyte synthesizes one molecule of squalene (C₃₀), how many molecules of (a) acetyl-CoA and (b) CO₂ are required or produced in the synthesis of the six IPP units needed?

Show answer

(a) Each IPP derives from one mevalonate, which requires 3 acetyl-CoA. Squalene requires 6 IPP units, so 6 × 3 = 18 acetyl-CoA. (b) Each mevalonate → IPP conversion releases 1 CO₂, so 6 CO₂ are produced during IPP formation. (Note: no additional CO₂ is released in the condensation of IPP units to form squalene; the additional 3 CO₂ in the overall cholesterol equation come from post-cyclization demethylation steps.)

Question 3: INTERMEDIATE

A patient is started on a statin drug. Predict the immediate and compensatory effects on: (i) hepatic HMG-CoA reductase mRNA levels, (ii) hepatic LDL receptor expression, and (iii) plasma LDL-cholesterol concentration. Explain the mechanism for each prediction.

Show answer

(i) Statin inhibition of HMG-CoA reductase decreases intracellular cholesterol, causing SCAP to release from Insig and escort SREBP-2 to the Golgi. Proteolytic release of the bHLH domain activates SRE-mediated transcription, so HMG-CoA reductase mRNA levels increase (compensatory upregulation). (ii) The same SREBP-2 activation also upregulates the LDL receptor gene, increasing LDL receptor expression on hepatocyte surfaces. (iii) More LDL receptors means greater hepatic uptake of circulating LDL particles, causing plasma LDL-cholesterol to decrease. This is the primary therapeutic mechanism by which statins lower cardiovascular risk. The net effect is that although the enzyme protein level rises, it is continuously inhibited by the drug, and the increased LDL receptor expression provides the clinical benefit.

Question 4: APPLIED

A researcher treats cultured fibroblasts with lovastatin and observes that, in addition to reduced cholesterol synthesis, the cells show impaired Ras signaling and decreased mitochondrial electron transport chain activity. Propose a biochemical explanation for these seemingly unrelated phenotypes, referencing the branching architecture of the mevalonate pathway.

Show answer

Lovastatin inhibits HMG-CoA reductase, thereby depleting all downstream isoprenoid products—not only cholesterol. Ras is a small GTPase that requires farnesylation (attachment of a C₁₅ farnesyl group derived from FPP) for membrane localization and signaling activity. Statin-induced depletion of FPP reduces Ras farnesylation, impairing its signaling function. Similarly, ubiquinone (CoQ₁₀) is synthesized from a polyisoprene tail derived from FPP; its depletion compromises electron transfer between Complexes I/II and Complex III in the mitochondrial electron transport chain. This experiment illustrates why the mevalonate pathway should be viewed as a branched biosynthetic network, and why chronic statin use occasionally causes myopathy—skeletal muscle is particularly sensitive to CoQ₁₀ depletion.

Question 5: CRITICAL THINKING

Oxysterols (such as 25-hydroxycholesterol) suppress SREBP processing, inhibit HMG-CoA reductase, and activate LXR-dependent transcription of cholesterol efflux genes (e.g., ABCA1). Design a hypothetical experiment to determine whether a novel synthetic oxysterol analog acts primarily through SREBP suppression or through LXR activation in reducing intracellular cholesterol. Include appropriate controls.

Show answer

One approach: use two cell lines—one with wild-type LXR and one with an LXR knockout (or dominant-negative LXR), both expressing functional SREBP machinery. Treat both lines with the novel oxysterol analog and measure (a) SREBP-2 cleavage (Western blot for nuclear SREBP-2), (b) HMG-CoA reductase mRNA and protein levels (qRT-PCR and Western blot), (c) ABCA1 mRNA (an LXR target gene), and (d) intracellular cholesterol mass (enzymatic assay or filipin staining). As controls, include cells treated with vehicle only, cells treated with 25-hydroxycholesterol (a known dual-acting oxysterol), and cells treated with a synthetic LXR agonist (e.g., T0901317). If the analog reduces cholesterol equally in both wild-type and LXR-knockout cells while suppressing SREBP processing, SREBP suppression is the dominant mechanism. If the analog fails to reduce cholesterol in LXR-knockout cells but is effective in wild-type cells, LXR activation is the primary effector. Intermediate phenotypes would suggest dual activity, which could be further dissected with dose-response analysis.

SUMMARY

Lesson Summary

Summary

Cholesterol biosynthesis proceeds through the mevalonate pathway, a four-stage process in which 18 acetyl-CoA molecules are condensed into mevalonate (C₆), decarboxylated to isopentenyl pyrophosphate (IPP, C₅), polymerized to the linear C₃₀ hydrocarbon squalene, and cyclized to lanosterol, which is then modified through ~19 further steps to yield cholesterol (C₂₇). The committed, rate-limiting enzyme is HMG-CoA reductase, regulated at four levels—transcription (SREBP), translation, degradation (Insig/ubiquitin), and phosphorylation (AMPK)—and is the target of statin drugs.

Beyond cholesterol, the pathway branches at farnesyl pyrophosphate (FPP) to produce ubiquinone (CoQ₁₀), dolichol, and prenylated signaling proteins (Ras, Rho). The overall process consumes 36 ATP and 16 NADPH per cholesterol molecule and requires molecular oxygen for the later cyclization and modification stages, making cholesterol synthesis an exclusively aerobic biosynthetic pathway. Understanding this network is essential for appreciating lipid homeostasis, cardiovascular pharmacology, and the metabolic basis of inborn errors of sterol synthesis.